MedTrace Logo

Evaluate the Efficacy and Safety of FB825 in Adult With Allergic Asthma

NCT05008965 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-01-12

No results posted yet for this study

Summary

This is a randomized, placebo-controlled and double-blind study to evaluate the efficacy and safety of FB825 in adult patients with moderate-to-severe allergic asthma.

Conditions

  • Allergic Asthma

Interventions

DRUG

FB825

FB825 will be administered at 8 mg/kg for the first dose and 4 mg/kg for the other five doses.

DRUG

Placebo

Placebo will be administered at 8 mg/kg for the first dose and 4 mg/kg for the other five doses.

Sponsors & Collaborators

  • Microbio Shanghai Co., Ltd.

    collaborator UNKNOWN

  • Oneness Biotech Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Sam Kuo · Oneness Biotech Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-27
Primary Completion
2027-12-31
Completion
2027-12-31
FDA Drug
Yes

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05008965 on ClinicalTrials.gov